NCT00317226View on ClinicalTrials.gov

Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

September 30, 2007

Conditions
Anemia
Interventions
DRUG

Ferric Carboxymaltose (FCM)

maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit

Trial Locations (1)

19403

Luitpold Pharmaceuticals Inc., Norristown

Sponsors
All Listed Sponsors
lead

American Regent, Inc.

INDUSTRY